Dawn Phenomenon in IDDM

Ernst A. Chantelau, Friedrich W. Kemmer, Gabriele E. Sonnenberg, Ingrid Mühlhauser, Achim Starke, Michael Berger, Peter J. Campbell, Geremia B. Bolli, Philip E. Cryer, John E. Gerich

Research output: Contribution to journalLetter

Abstract

To the Editor: In their recent article on the pathogenesis of the dawn phenomenon, Campbell et al. (June 6 issue)1 conclude that nocturnal surges of growth hormone were predominantly responsible for the progressive increase in glycemia that they observed in six (or seven) insulin-dependent diabetic patients with unsatisfactory metabolic control (mean glycosylated hemoglobin, 2.2 per cent above the normal range) during intravenous insulin infusion. As a consequence, the authors suggested the administration of a somatostatin analogue before bedtime in order to suppress nocturnal growth hormone secretion, as an approach to prevent the dawn phenomenon in Type I (insulin-dependent) diabetes mellitus.

Original languageEnglish
Pages (from-to)957-958
Number of pages2
JournalNew England Journal of Medicine
Volume313
Issue number15
DOIs
StatePublished - Oct 10 1985
Externally publishedYes

Fingerprint Dive into the research topics of 'Dawn Phenomenon in IDDM'. Together they form a unique fingerprint.

  • Cite this

    Chantelau, E. A., Kemmer, F. W., Sonnenberg, G. E., Mühlhauser, I., Starke, A., Berger, M., Campbell, P. J., Bolli, G. B., Cryer, P. E., & Gerich, J. E. (1985). Dawn Phenomenon in IDDM. New England Journal of Medicine, 313(15), 957-958. https://doi.org/10.1056/NEJM198510103131514